Resistance profile of children and adolescents infected with HIV-1 in urban areas in Togo

2018 ◽  
Vol 28 (4) ◽  
pp. 419-423
Author(s):  
O.E. Takassi ◽  
M. Salou ◽  
K.E. Djadou ◽  
F. Agbéko ◽  
D. Agbèrè ◽  
...  
HIV Medicine ◽  
2021 ◽  
Author(s):  
Daniele Armenia ◽  
Yagai Bouba ◽  
Roberta Gagliardini ◽  
Lavinia Fabeni ◽  
Vanni Borghi ◽  
...  

Author(s):  
Chris Nadège Nganou‐Gnindjio ◽  
Doris Bibi Essama ◽  
Jan René Nkeck ◽  
Patrick Yvan Tchebegna ◽  
Kiliane Maeva Tchatchouang ◽  
...  

1996 ◽  
Vol 3 (4) ◽  
pp. 301-314 ◽  
Author(s):  
C. Nicholas Hodge ◽  
Paul E. Aldrich ◽  
Lee T. Bacheler ◽  
Chong-Hwan Chang ◽  
Charles J. Eyermann ◽  
...  

Author(s):  
Julia Rehling ◽  
Christiane Bunge ◽  
Julia Waldhauer ◽  
André Conrad

Public green spaces have a high potential for a positive impact on people’s health and wellbeing, especially in urban areas. Studies on environmental justice indicate socially unequal access possibilities to urban green spaces. This article presents results on associations between individual socioeconomic position (SEP) and walking time from home to public green spaces in young people living in urban areas with more than 20,000 inhabitants in Germany. Data were derived from the German Environmental Survey for Children and Adolescents 2014–2017 (GerES V), the environmental module of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS Wave 2). The sample comprises 1149 participants aged 3 to 17 years. A total of 51.5% of the participants reach a public green space on foot within five and 72.8% within ten minutes from home. The lower the participant’s SEP, the longer the walking time. Logistic regression models controlling for age group, sex, migration background, and region of residence show that participants with a low SEP have a significantly higher risk (odds ratio = 1.98; 95% confidence interval: 1.31–2.99) of needing more than ten minutes to walk from home to a public green space than participants with a high SEP. GerES V data indicate that young people living in urban areas in Germany do not equally benefit from the health-promoting potential of green spaces, which is an important aspect of environmental health inequalities.


Author(s):  
Flávia Jacqueline Almeida ◽  
Rosangela Rodrigues ◽  
Mayra Simioni Zaparoli ◽  
Eitan Naaman Berezin ◽  
Marco Aurélio Palazzi Sáfadi ◽  
...  

AIDS ◽  
2006 ◽  
Vol 20 (4) ◽  
pp. 483-494 ◽  
Author(s):  
Heather B Jaspan ◽  
Stephen D Lawn ◽  
Jeffrey T Safrit ◽  
Linda-Gail Bekker

2007 ◽  
Vol 51 (11) ◽  
pp. 4036-4043 ◽  
Author(s):  
Serge Dandache ◽  
Guy Sévigny ◽  
Jocelyn Yelle ◽  
Brent R. Stranix ◽  
Neil Parkin ◽  
...  

ABSTRACT Despite the success of highly active antiretroviral therapy, the current emergence and spread of drug-resistant variants of human immunodeficiency virus (HIV) stress the need for new inhibitors with distinct properties. We designed, produced, and screened a library of compounds based on an original l-lysine scaffold for their potentials as HIV type 1 (HIV-1) protease inhibitors (PI). One candidate compound, PL-100, emerged as a specific and noncytotoxic PI that exhibited potent inhibition of HIV-1 protease and viral replication in vitro (Ki , ∼36 pM, and 50% effective concentration [EC50], ∼16 nM, respectively). To confirm that PL-100 possessed a favorable resistance profile, we performed a cross-resistance study using a panel of 63 viral strains from PI-experienced patients selected for the presence of primary PI mutations known to confer resistance to multiple PIs now in clinical use. The results showed that PL-100 retained excellent antiviral activity against almost all of these PI-resistant viruses and that its performance in this regard was superior to those of atazanavir, amprenavir, indinavir, lopinavir, nelfinavir, and saquinavir. In almost every case, the increase in the EC50 for PL-100 observed with viruses containing multiple mutations in protease was far less than that obtained with the other drugs tested. These data underscore the potential for PL-100 to be used in the treatment of drug-resistant HIV disease and argue for its further development.


PLoS ONE ◽  
2013 ◽  
Vol 8 (5) ◽  
pp. e62552 ◽  
Author(s):  
Sabri Saeed Sanabani ◽  
Rodrigo Pessôa ◽  
Ana Carolina Soares de Oliveira ◽  
Vanessa Pouza Martinez ◽  
Maria Teresa Maidana Giret ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document